MCL Literature Feed

Seven-year follow-up of venetoclax-ibrutinib in relapsed/refractory MCL shows durable responses (30% PFS) and demonstrates feasibility of MRD-guided treatment-free remission, supporting a long-term chemotherapy-free strategy.

This case of atypical plasma cell leukemia, initially misdiagnosed as blastoid mantle cell lymphoma, highlights the critical diagnostic challenge of distinguishing between aggressive, morphologically similar hematologic malignancies.

A survey of US and European hematologists reveals significant knowledge gaps in MCL guidelines, molecular testing, and toxicity management, highlighting a need for improved continuing medical education.

Preclinical models show the PI3K inhibitor idelalisib synergizes with the CDK4/6 inhibitor palbociclib, providing a rationale for a novel combination therapy in relapsed/refractory MCL.

This case report details an extremely rare presentation of relapsed mantle cell lymphoma as an appendiceal volvulus, highlighting an unusual cause of acute abdominal pain requiring emergent surgery.

This review summarizes the evolving treatment landscape for relapsed/refractory MCL, highlighting survival gains from BTKi and CAR-T and outlining emerging therapies like bispecifics for multiply-refractory patients.

This large, real-world study confirms cytarabine-based induction provides the longest front-line PFS (68 months), while second-line chemotherapy outcomes are poor (14 months PFS), highlighting the need for novel agents.

A rare case of MCL presenting as diffuse polyposis throughout the entire GI tract achieved complete response after R-CHOP followed by salvage chemotherapy plus ibrutinib, highlighting this unusual presentation.

This case report details the practical challenges and potential toxicities of administering CAR-T cell therapy to an elderly MCL patient with high tumor burden, informing management of this high-risk group.

This study analyzes molecular responses in exceptional responders to the BTKi tirabrutinib, aiming to identify biomarkers for deep, durable remissions in relapsed/refractory mantle cell lymphoma.

This commentary evaluates rituximab's evolving role in MCL, questioning its necessity in modern chemo-free regimens and its place alongside novel targeted agents.

This multicenter real-world study demonstrates that CAR-T therapy can be an effective treatment for MCL patients with secondary CNS involvement, a population with historically poor outcomes.

This review highlights BTK's non-catalytic scaffolding function as a novel mechanism of BTKi resistance, presenting a new therapeutic target beyond kinase inhibition for treating B-cell lymphomas like MCL.

CD20-targeted CAR-T therapy induced durable remissions (>7 years) in MCL by triggering a lasting endogenous anti-tumor immune response (epitope spreading) despite a lack of CAR-T persistence.

The dual HCK/BTK inhibitor KIN-8194 preclinically overcomes primary and acquired BTKi resistance in MCL by targeting HCK-mediated growth and adhesion, offering a novel therapeutic strategy.

The R-GEMOX (rituximab, gemcitabine, oxaliplatin) chemotherapy regimen demonstrates efficacy as a salvage option for patients with relapsed/refractory mantle cell lymphoma in a phase I/II study.

Bendamustine is a feasible alternative lymphodepletion for brexu-cel in MCL, showing comparable efficacy to standard cy/flu with less cytopenia, providing a critical option during drug shortages.

The CDK9 inhibitor enitociclib overcomes resistance to both BTK inhibitors and CAR-T therapy, offering a potential new strategy for double-refractory mantle cell lymphoma.

Adding bortezomib to R-HAD chemotherapy for relapsed/refractory MCL significantly improved time to treatment failure (12 vs 2.6 months), providing a valuable option when BTK inhibitors are unavailable.

The non-covalent BTK inhibitor pirtobrutinib demonstrates efficacy in mantle cell lymphoma patients who have progressed on prior covalent BTKi therapy, overcoming a common resistance mechanism.

This UK real-world, intention-to-treat analysis of brexu-cel confirms high efficacy in infused patients but reveals a 30% attrition rate before infusion and significant non-relapse mortality from infection.

This case report demonstrates delayed Hepatitis B reactivation with acalabrutinib in relapsed MCL, underscoring the need for viral screening and prophylaxis with second-generation BTK inhibitors.

This retrospective study confirms that progression of disease within 24 months (POD24) after initial therapy is a strong negative prognostic marker for overall survival in MCL patients.

This review summarizes the clinical data and rationale for targeted agents like BTK and BCL2 inhibitors, highlighting the paradigm shift away from chemotherapy in both relapsed/refractory and frontline MCL.

Transformed MCL with triple-hit genetics (MYC/BCL2/BCL6 rearrangements) can be resistant to BTK inhibitors, identifying a novel genomic mechanism of treatment failure in this aggressive setting.

This review details the evolution of BTK inhibitors, highlighting improved toxicity with newer agents and the emergence of non-covalent BTKis and novel resistance mutations, impacting MCL treatment sequencing.

This phase 1/2 trial establishes the safety and efficacy of the BTKi acalabrutinib in Chinese patients with relapsed/refractory MCL, supporting its use in this specific population.

This commentary discusses the zandelisib (PI3Ki) plus zanubrutinib (BTKi) combination, suggesting a potential role for newer, potentially less toxic PI3K inhibitors in relapsed/refractory MCL.

This review positions allogeneic transplant as a key curative option for high-risk (e.g., TP53-mutated) and relapsed/refractory MCL, despite its changing role with the advent of novel therapies.

In a European compassionate use program, pirtobrutinib demonstrated a 67% overall response rate and good safety in heavily pretreated, BTKi-exposed relapsed/refractory MCL, supporting its real-world clinical utility.